Dietz S M, van Stijn D, Burgner D, Levin M, Kuipers I M, Hutten B A, Kuijpers T W
Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Childrens Hospital, Academic Medical Centre (AMC), Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Murdoch Childrens Research Institute, Parkville, VIC, Australia.
Eur J Pediatr. 2017 Aug;176(8):995-1009. doi: 10.1007/s00431-017-2937-5. Epub 2017 Jun 27.
Kawasaki disease (KD) is a pediatric vasculitis with coronary artery aneurysms (CAA) as its main complication. The diagnosis is based on the presence of persistent fever and clinical features including exanthema, lymphadenopathy, conjunctival injection, and changes to the mucosae and extremities. Although the etiology remains unknown, the current consensus is that it is likely caused by an (infectious) trigger initiating an abnormal immune response in genetically predisposed children. Treatment consists of high dose intravenous immunoglobulin (IVIG) and is directed at preventing the development of CAA. Unfortunately, 10-20% of all patients fail to respond to IVIG and these children need additional anti-inflammatory treatment. Coronary artery lesions are diagnosed by echocardiography in the acute and subacute phases. Both absolute arterial diameters and z-scores, adjusted for height and weight, are used as criteria for CAA. Close monitoring of CAA is important as ischemic symptoms or myocardial infarction due to thrombosis or stenosis can occur. These complications are most likely to arise in the largest, so-called giant CAA. Apart from the presence of CAA, it is unclear whether KD causes an increased cardiovascular risk due to the vasculitis itself.
Many aspects of KD remain unknown, although there is growing knowledge on the etiology, treatment, and development and classification of CAA. Since children with previous KD are entering adulthood, long-term follow-up is increasingly important. What is known: • Kawasaki disease (KD) is a pediatric vasculitis with coronary artery damage as its main complication. • Although KD approaches its 50th birthday since its first description, many aspects of the disease remain poorly understood. What is new: • In recent years, multiple genetic candidate pathways involved in KD have been identified, with recently promising information about the ITPKC pathway. • As increasing numbers of KD patients are reaching adulthood, increasing information is available about the long-term consequences of coronary artery damage and broader cardiovascular risk.
川崎病(KD)是一种小儿血管炎,主要并发症为冠状动脉瘤(CAA)。诊断基于持续发热以及包括皮疹、淋巴结病、结膜充血和黏膜及四肢变化等临床特征。尽管病因尚不清楚,但目前的共识是,它可能由(感染性)触发因素引发,在具有遗传易感性的儿童中引发异常免疫反应。治疗包括大剂量静脉注射免疫球蛋白(IVIG),旨在预防CAA的发生。不幸的是,所有患者中有10 - 20%对IVIG无反应,这些儿童需要额外的抗炎治疗。在急性期和亚急性期通过超声心动图诊断冠状动脉病变。绝对动脉直径和根据身高及体重调整的z评分均用作CAA的标准。密切监测CAA很重要,因为可能会出现因血栓形成或狭窄导致的缺血症状或心肌梗死。这些并发症最有可能发生在最大的所谓巨大CAA中。除了存在CAA外,尚不清楚KD是否因其血管炎本身而导致心血管风险增加。
尽管对川崎病的病因、治疗以及CAA的发展和分类的认识不断增加,但川崎病的许多方面仍然未知。由于曾患川崎病的儿童正步入成年期,长期随访变得越来越重要。已知信息:• 川崎病(KD)是一种以冠状动脉损伤为主要并发症的小儿血管炎。• 尽管自首次描述以来川崎病已近50年,但该疾病的许多方面仍知之甚少。新信息:• 近年来,已确定了多个与川崎病相关的遗传候选途径,最近关于ITPKC途径有了有前景的信息。• 随着越来越多的川崎病患者成年,关于冠状动脉损伤的长期后果和更广泛的心血管风险的信息也越来越多。